These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37087470)

  • 1. Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, And AGS).
    Kanazawa N; Ishii T; Takita Y; Nishikawa A; Nishikomori R
    Pediatr Rheumatol Online J; 2023 Apr; 21(1):38. PubMed ID: 37087470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.
    Sanchez GAM; Reinhardt A; Ramsey S; Wittkowski H; Hashkes PJ; Berkun Y; Schalm S; Murias S; Dare JA; Brown D; Stone DL; Gao L; Klausmeier T; Foell D; de Jesus AA; Chapelle DC; Kim H; Dill S; Colbert RA; Failla L; Kost B; O'Brien M; Reynolds JC; Folio LR; Calvo KR; Paul SM; Weir N; Brofferio A; Soldatos A; Biancotto A; Cowen EW; Digiovanna JJ; Gadina M; Lipton AJ; Hadigan C; Holland SM; Fontana J; Alawad AS; Brown RJ; Rother KI; Heller T; Brooks KM; Kumar P; Brooks SR; Waldman M; Singh HK; Nickeleit V; Silk M; Prakash A; Janes JM; Ozen S; Wakim PG; Brogan PA; Macias WL; Goldbach-Mansky R
    J Clin Invest; 2018 Jul; 128(7):3041-3052. PubMed ID: 29649002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China.
    Li W; Wang W; Wang W; Zhong L; Gou L; Wang C; Ma J; Quan M; Jian S; Tang X; Zhang Y; Wang L; Ma M; Song H
    Front Immunol; 2022; 13():825367. PubMed ID: 35418997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology Points to Consider for Diagnosis and Management of Autoinflammatory Type I Interferonopathies: CANDLE/PRAAS, SAVI, and AGS.
    Cetin Gedik K; Lamot L; Romano M; Demirkaya E; Piskin D; Torreggiani S; Adang LA; Armangue T; Barchus K; Cordova DR; Crow YJ; Dale RC; Durrant KL; Eleftheriou D; Fazzi EM; Gattorno M; Gavazzi F; Hanson EP; Lee-Kirsch MA; Montealegre Sanchez GA; Neven B; Orcesi S; Ozen S; Poli MC; Schumacher E; Tonduti D; Uss K; Aletaha D; Feldman BM; Vanderver A; Brogan PA; Goldbach-Mansky R
    Arthritis Rheumatol; 2022 May; 74(5):735-751. PubMed ID: 35315249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS.
    Cetin Gedik K; Lamot L; Romano M; Demirkaya E; Piskin D; Torreggiani S; Adang LA; Armangue T; Barchus K; Cordova DR; Crow YJ; Dale RC; Durrant KL; Eleftheriou D; Fazzi EM; Gattorno M; Gavazzi F; Hanson EP; Lee-Kirsch MA; Montealegre Sanchez GA; Neven B; Orcesi S; Ozen S; Poli MC; Schumacher E; Tonduti D; Uss K; Aletaha D; Feldman BM; Vanderver A; Brogan PA; Goldbach-Mansky R
    Ann Rheum Dis; 2022 May; 81(5):601-613. PubMed ID: 35086813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies.
    Kim H; Gunter-Rahman F; McGrath JA; Lee E; de Jesus AA; Targoff IN; Huang Y; O'Hanlon TP; Tsai WL; Gadina M; Miller FW; Goldbach-Mansky R; Rider LG
    Arthritis Res Ther; 2020 Apr; 22(1):69. PubMed ID: 32252809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Janus Kinase Inhibitors in Type I Interferon-Mediated Monogenic Autoinflammatory Disorders: A Scoping Review.
    Gómez-Arias PJ; Gómez-García F; Hernández-Parada J; Montilla-López AM; Ruano J; Parra-Peralbo E
    Dermatol Ther (Heidelb); 2021 Jun; 11(3):733-750. PubMed ID: 33856640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferonopathies: From concept to clinical practice.
    Mendonça LO; Frémond ML
    Best Pract Res Clin Rheumatol; 2024 Sep; 38(3):101975. PubMed ID: 39122631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease flares with baricitinib dose reductions and development of flare criteria in patients with CANDLE/PRAAS.
    Cetin Gedik K; Ortega-Villa AM; Materne G; Rastegar A; Montealegre Sanchez GA; Reinhardt A; Brogan PA; Berkun Y; Murias S; Robles M; Schalm S; de Jesus AA; Goldbach-Mansky R
    Ann Rheum Dis; 2024 Aug; 83(9):1181-1188. PubMed ID: 38653530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baricitinib experience on STING-associated vasculopathy with onset in infancy: A representative case from Turkey.
    Balci S; Ekinci RMK; de Jesus AA; Goldbach-Mansky R; Yilmaz M
    Clin Immunol; 2020 Mar; 212():108273. PubMed ID: 31626957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus.
    Kim H; Sanchez GA; Goldbach-Mansky R
    J Mol Med (Berl); 2016 Oct; 94(10):1111-1127. PubMed ID: 27678529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome.
    Volpi S; Insalaco A; Caorsi R; Santori E; Messia V; Sacco O; Terheggen-Lagro S; Cardinale F; Scarselli A; Pastorino C; Moneta G; Cangemi G; Passarelli C; Ricci M; Girosi D; Derchi M; Bocca P; Diociaiuti A; El Hachem M; Cancrini C; Tomà P; Granata C; Ravelli A; Candotti F; Picco P; DeBenedetti F; Gattorno M
    J Clin Immunol; 2019 Jul; 39(5):476-485. PubMed ID: 31144250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toward a better understanding of type I interferonopathies: a brief summary, update and beyond.
    Yu ZX; Song HM
    World J Pediatr; 2020 Feb; 16(1):44-51. PubMed ID: 31377974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease course and treatment effects of a JAK inhibitor in a patient with CANDLE syndrome.
    Boyadzhiev M; Marinov L; Boyadzhiev V; Iotova V; Aksentijevich I; Hambleton S
    Pediatr Rheumatol Online J; 2019 May; 17(1):19. PubMed ID: 31046790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Type I interferonopathies].
    Munoz J; Marque M; Dandurand M; Meunier L; Crow YJ; Bessis D
    Ann Dermatol Venereol; 2015 Nov; 142(11):653-63. PubMed ID: 26363997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type 1 interferonopathy presenting as juvenile idiopathic arthritis with interstitial lung disease: report of a new phenotype.
    Clarke SLN; Robertson L; Rice GI; Seabra L; Hilliard TN; Crow YJ; Ramanan AV
    Pediatr Rheumatol Online J; 2020 May; 18(1):37. PubMed ID: 32398023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome-associated autoinflammatory syndromes: advances in pathogeneses, clinical presentations, diagnosis, and management.
    McDermott A; Jacks J; Kessler M; Emanuel PD; Gao L
    Int J Dermatol; 2015 Feb; 54(2):121-9. PubMed ID: 25521013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Autoinflammatory syndromes in childhood].
    Horneff G
    Z Rheumatol; 2015 Aug; 74(6):511-24; quiz 525. PubMed ID: 26238708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nakajo-Nishimura syndrome and related proteasome-associated autoinflammatory syndromes.
    Ohmura K
    J Inflamm Res; 2019; 12():259-265. PubMed ID: 31576159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematologic abnormalities in Aicardi Goutières Syndrome.
    Adang LA; Gavazzi F; D'Aiello R; Isaacs D; Bronner N; Arici ZS; Flores Z; Jan A; Scher C; Sherbini O; Behrens EM; Goldbach-Mansky R; Olson TS; Lambert MP; Sullivan KE; Teachey DT; Witmer C; Vanderver A; Shults J
    Mol Genet Metab; 2022 Aug; 136(4):324-329. PubMed ID: 35786528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.